Antisense oligonucleotides as therapeutics for hyperlipidaemias

Expert Opinion on Biological Therapy

Volumn 5, Issue 7, 2005, Pages 907-917

  Crooke, Rosanne M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Apolipoprotein B 100; Apolipoprotein C III; CHD; Hyperlipidaemia; LDL C; RNA interference; RNAi; siRNA; Small interfering RNA; TGs; Triglycerides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; CHOLESTEROL; CHYLOMICRON; CYTOCHROME P450; FIBRIC ACID DERIVATIVE; FOMIVIRSEN; ISIS 301012; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT RNA; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BLOATING; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FATTY ACID OXIDATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSTIMULATION; KIDNEY CLEARANCE; LIPID METABOLISM; NONHUMAN; ORGAN DISTRIBUTION; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; RETINITIS; REVIEW; STEATORRHEA;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 22744434640     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.7.907     Document Type: Review

References (126)

1. BRAUNWALD E: Shattuck Lecture - Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. (1997) 337:1360-1369. Excellent review of cardiovascular medicine and disease.
2. DAVIS RA, HUI TY: 2000 George Lyman Duff Memorial Lecture. Atherosclerosis is a liver disease of the heart. Arterioscler. Thromb. Vasc. Biol. (2001) 21:887-898. This article shows the importance of liver for the development of cardiovascular disease.
3. BONOW RO: Primary prevention of cardiovascular disease. A call to action. Circulation (2002) 106:3140-3141.
4. NO AUTHORS LISTED: Mean Disease And Stroke Statistics - 2003 Update. American Heart Association (2003):1-42.
5. MAHLEY RW, BERSOT TP: Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. (10th ed.). Hardman JG, Limbard LE (Eds.), McGraw-Hill Medical Publishing Division, New York, NY, USA (2001):971-1002. General review of lipid-lowering therapies.
6. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Exective Summary Of The Third Report Of The National Cholesterol Education Program (NCEP) Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486-2497.
7. GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation (2004) 110:227-239.
8. DURRINGTON P: Dyslipidemia. Lancet (2003) 362:717-731.
9. KNOPP RH: Drug treatment of lipid disorders. N. Engl. J. Med. (1999) 341:498-511.
10. LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1339-1357.
11. DOWNS GR, CLEARFIELD M, WEISS S: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TEXCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA (1998) 279:1615-1622.
12. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301-1307.
13. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high risk individuals: a randomized placebo controlled trial. Lancet (2002) 360:7-22.
14. HULTHE J, FAGERBERG B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler. Thromb. Vasc. Biol. (2002) 22:1162-1167.
15. SKALEN K, GUSTAFSSON M, RYDBERG EK et al.: Subendothelial retetion of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 417:750-754.
16. GOTTO AM: Management of dyslipidemia. Am. J. Med. (2002) 112:10S-18S.
17. GINSBERG HN: New perspectives on atherogenesis. Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation (2002) 106:2137-2142.
18. ASIA PACIFIC COHORT STUDIES COLLABORATION: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific Region. Circulation (2004) 110:2678-2686.
19. TANNE D, KOREN-MORAG N, GRAFF E, GOLDBOURT U: Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate infarcation prevention (BIP) registry. High triglycerides constitute an independent risk factor. Circulation (2001) 104:2892-2897.
20. ABOOKIRE SA, KARSON AS, FISKIO J, BATES DW: Use and monitoring of statin lipid-lowering drugs compared with guidelines. Arch. Int. Med. (2001) 161:53-58.
21. AHMED SM, CLASEN ME, DONNELLY JE: Management of dyslipidemia in adults. Am. Fam. Physician (1998) 57:2192-2204.
22. BOCAN TM: Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Invest. Drugs (2002) 3:21-27.
23. WIERZBICKI AS: Lipid-lowering therapies in development. Expert Opin. Invest. Drugs (2004) 13(11):1405-1418.
24. SUETA CA, MASSING MW, CHOWDHURY M, BIGGS DP, SIMPSON RJ: Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J. Cardiac Failure (2003) 9:36-41.
25. PEARSON TA, LAURORA I, CHU H, KAFONEK S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Int. Med. (2000) 160:459-467.
26. ROSS EM, KENAKIN TP: Pharmacodynamics. Mechanisms of drug action and relationship between drug concentration and effect. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th ed.). Hardman JG, Limbard LE (Eds.), McGraw-Hill Medical Publishing Division, New York, NY, USA (2001):31-43.
27. CROOKE ST: Progress in antisense technology. Annu. Rev. Med. (2004) 55:61-95. Excellent review of antisense technology and the antisense drugs in clinical development.
28. CROOKE ST: Molecular mechanism of action of antisense drugs. Biochem. Biophys. Acta (1999) 1489:31-44.
29. CROOKE ST: Basic principles of antisense technology. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):1-27.
30. BENNETT CF: Efficiency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev. (2002) 12:215-224. Highlights the efficiency of drug discovery using the antisense platform.
31. CROOKE ST: Molecular mechanisms of antisense drugs: human RNase H. Antisense Nucleic Acid Drug Dev. (1999) 9:377-379.
32. LIMA WF, WU H, CROOKE ST: Human RNases H. In: Methods in Enzymology. Academic Press, San Diego, CA, USA (2001):430-440. Illustrates the importance of RNases H.
33. WU H, LIMA WF, ZHANG H, FAN A, SUN H, CROOKE ST: Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. (2004) 279(17):17181-17189.
34. CROOKE ST: Antisense strategies. Curr. Mol. Med. (2004) 4(5):465-487.
35. CAPLEN NJ: RNAi as a gene therapy approach. Expert Opin. Biol. Ther. (2003) 3(4):575-586. Excellent review of RNAi.
36. CAPLEN NJ, PARRISH S, IMANI F, FIRE A, MORGAN RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA (2001) 98:9742-9747.
37. CROOKE RM: Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphoate oligonucleotides. In: Antisense Research and Applications. Crooke ST, Lebleu B (Eds), CRC Press, Boca Raton, FL, USA (1993):427-449.
38. COOK PD: Medicinal chemistry of antisense oligonucleotides. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):29-56.
39. UHLMANN E, PEYMANN A: Antisense oligonucleotides. A new therapeutic principle. Chem. Rev. (1990) 90:543-584.
40. MANOHARAN M: Oligonucleotide conjugates in antisense technology. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):391-469.
41. GOODCHILD J: Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconjug. Chem. (1990) 1:166-187.
42. RAYNER B, MALVY C, PAOLETTE J et al.: α-Oligodeoxynucleotide analogues. In: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Cohen J (Ed.) CRC Press, Boca Raton, FL, USA (1989):119-136.
43. HENRY SP, GEARY RS, YU R, LEVIN AA: Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Invest. Drugs (2001) 2(10):1444-1449.
44. LEVIN AA, HENRY SP, MONTEITH D, TEMPLIN MV: Toxicity of antisense oligonucleotides. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):201-267.
45. ZELLWEGER T, MIYAKE H, COOPER S et al.: Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. (2001) 298:934-940.
46. SEWELL KL, GEARY RS, BAKER BF et al.: Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J. Pharmacol. Exp. Ther. (2002) 303:1334-1343.
47. DEAN NM, BUTLER M, MONIA BP, MANOHARAN M: Pharmacology of 2′-O (2-methoxy)ethyl modified antisense oligonucleotides. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):319-338.
48. GEARY RS, WATANABE TA, TROUNG L et al.: Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotides in rat. J. Pharmacol. Exp. Ther. (2001) 296:890-897.
49. YU R, GEARY RS, MONTEITH DK, MATSON J et al.: Tissue disposition of 2′-O-(2-methoxy)ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. (2004) 93(1):48-59.
50. GEARY RS, YU RZ, LEEDS JM et al.: Pharmacokinetic properties in animals. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):119-154.
51. CROOKE RM, GRAHAM MJ: Suborgan pharmacokinetics. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):155-182.
52. YU RZ, GEARY RS, WATANABE TA, LEVIN AA, SCHOENFELD SL: Pharmacokinetic properties in humans. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):183-200.
53. GLOVER JM, LEEDS JM, MANT TG et al.: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. (1997) 282:1173-1180.
54. ZHANG R, YAN J, SHAHINIAN H et al.: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. (1995) 58:44-53.
55. ZHANG H, COOK J, NICKEL J et al.: Reduction of liver fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. (2000) 18:862-867.
56. GEARY RS, WATANABE TA, TROUNG L et al.: Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotides in rat. J. Pharmacol. Exp. Ther. (2001) 296:890-897.
57. CUNNINGHAM CC, HOLMLUND JT, GEARY RS et al.: A Phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. (2000) 6(5):1626-1631.
58. GEARY RS, KHATSENKO O, BUNKER K et al.: Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal installation in rats. J. Pharmacol. Exp. Ther. (2001) 296:898-904.
59. KHATSENKO O, MORGAN R, TRUONG L et al.: Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length. Antisense Nucleic Acid Drug Dev. (2000) 10:35-44.
60. HARDEE GE, WEINBACH SP, TILLMAN LG: New routes and novel formulations for delivery of antisense oligonucleotides. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):795-832.
61. LEVIN AA, MONTEITH DK, LEEDS JM et al.: Toxicity of oligodeoxynucleotide therapeutic agents. In: Antisense Research and Application. Crooke ST (Ed.), Springer-Verlag, Heidelberg, Germany (1998):169-215.
62. HENRY SP, TAYLOR J, MIDGLEY L, LEVIN AA, KORNBRUST DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. (1997) 7:473-481.
63. SARMIENTO UM, PEREZ JR, BECKER JM, RAMASWAMY N: In vivo toxicological effects of a rel A antisense phosphorothioate in CD-1 mice. Antisense Res. Dev. (1994) 4:99-107.
64. MONTEITH DK, GEARY RS, JOHNSTON J, MONIA BP, LEVIN AA: Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. (1998) 46:365-375.
65. KRIEG AM: Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochem. Biophys. Acta (1999) 1489:107-116.
66. MONTEITH DK, HENRY SP, HOWARD RB et al.: Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. (1997) 12:421-432.
67. HENRY S, STECKER K, BROOKS D et al.: Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. (2001) 292:468-479.
68. HENRY SP, MONTEITH D, LEVIN AA: Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. (1997) 12:395-408.
69. GALBRAITH WM, HOBSON WC, GICLAS PC, SCHECTER PJ, AGRAWAL S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in monkey. Antisense Res. Dev. (1994) 4:201-206.
70. HENRY SP, GICLAS PC, LEEDS J et al.: Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide:potential mechanism of action. J. Pharmacol. Exp. Ther. (1997) 281:810-816.
71. CORNISH KG, IVERSEN P, SMITH L, ARNESON M, BAYEVER E: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. (1993) 3:239-247.
72. WALLACE TL, BAZEMORE SA, KORNBRUST DJ, COSSUM PA: Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. (1996) 278:1306-1312.
73. HENRY SP, NOVOTNY W, LEEDS J, AULETTA C, KORNBRUST DJ: Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. (1997) 7:503-510.
74. NICKLIN PL, AMBLER J, MITCHELSON A et al.: Preclinical profiling of modified oligonucleotides: anticoagulant and pharmacokinetic properties. Proc. Natl. Acad. Sci. USA (1997) 16:1145-1153.
75. HENRY SP, LARKIN R, NOVOTNY WF, KORNBRUST DJ: Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharm. Res. (1994) 11:5353.
76. DORR FA, GLOVER JG, KWOH JT: Clinical safety of phosphorothioate oligodeoxynucleotides. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., USA New York, NY, USA (2001):269-290.
77. GRILLONE LR: The development of antisense oligonucleotides as antivirals. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):725-738.
78. HOLMLUND JT: Clinical activities in patients with solid tumors or lymphoma. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):739-759.
79. HOLMLUND JT: Applying antisense technology. Affinitak™ and other antisense oligonucleotides in clinical development. Ann. NY Acad. Sci. (2003) 1002:244-251. Good review of antisense compounds in the clinic.
80. GEWIRTZ AM: Nucleic acid therapeutics for the treatment of human leukemia. In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):761-771.
81. SHANAHAN WR JR: ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1 (ICAM-1). In: Antisense Technology: Principles, Strategies and Applications. Crooke ST (Ed.), Marcel Dekker, Inc., New York, NY, USA (2001):772-794.
82. PACHEO G, HENRY SP, GEARY R, DEPEYSTER A: Characterization of nonspecific effects of phosphorothioate antisense oligodeoxynulceotides on cytochrome P450 3A2 and cytochrome P450 2CII in male Sprague-Dawley rats. Toxicologist (2002) 66:22.
83. CROOKE RM, GRAHAM MJ, LEMONIDIS KM et al.: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. (2005) 46:872-884. Detailed description of the preclinical pharmacology of the 2′ MOE ASO to apoB-100.
84. BRADLEY JD, GRAHAM M, HENRY SH et al.: Evaluation of ISIS 301012, an antisense inhibitor to human apoB-100 in healthy volunteers. XV International Symposium on Drugs Affecting Lipid Metabolism Abstract Book. (2004):37.
85. SENIOR K: Antisense inhibitor provides new treatment approach for hypercholesterolaemia. Drug Disc. Today (2002) 7:840-841.
86. DAVIDSON NO, SHELNESS GS: Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. (2000) 20:169-93. Excellent description of the production of apoB-containing lipoproteins.
87. MARSH JB, WELTY JB, LICHTENSTEIN AH, LAMON-FAVA S, SCHAEFER EJ: Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis (2000) 162:227-224.
88. DAS HK, LEFF T, BRESLOW JL: Cell type-specific expression of the human apoB gene is controlled by two cis-acting regulatory regions. J. Biol. Chem. (1998) 263:11452-11458.
89. OLOFFSON SV, STILLEMARK-BILLTON P, ASP L: Intracellular assembly of VLDL. Two major steps in separate cell compartments. Trends Cardiovasc. Med. (2001) 10:338-345.
90. SHELNESS GS, SELLERS SA: Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. (2001) 12:151-157.
91. PEASE RJ, LEIPER JM: Regulation of hepatic apolipoprotein-B-containing lipoproteins secretion. Curr. Opin. Lipidol. (1996) 7:132-138.
92. KANE JP, HAVEL RJ: Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, NY, USA (2001):2717-2751. Excellent clinical descriptions of disorders involving apoB-containing lipoproteins.
93. GAFFNEY D, FORSTER L, CASLAKE MJ et al.: Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis (2002) 162:33-43.
94. VEERKAMP MJ, DE GRAAF J, BREDIE JC, HENDRICKS PN, STALENHOEF AF: Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families. Results of a 5year follow-up study. Arterioscler. Thromb. Vasc. Biol. (2002) 22:274-282.
95. TYBJAERG-HANSEN A, STEFFENSEN R, MEINERTZ H, SCHNOHR P, NORDESTGAARD BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N. Engl. J. Med. (1998) 338:1577-1584.
96. GREEVENBROEK MM, VERMEULEN VM, DEBRUIN TW: Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome. J. Lipid. Res. (2002) 43:1846-1854.
97. BOREN J, LEE I, ZHU W, ARNOLD K, TAYLOR S, INNERARITY TL: Identification of the low density lipoprotein receptor-binding site in apolipoprotein B-100 and the modulation of its binding activity by the carboxy terminus in familial defective apoB-100. J. Clin. Invest. (1998) 101:1084-1093.
98. CHAN DC, WATTS GF, BARRETT HR, BEILIN LJ, REDGRAVE TG, MORI TA: Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes (2002) 51:2377-2386.
99. GRUNDY SM: Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome. Am. J. Cardiol. (1998) 81:18B-25B.
100. CHAN DC, WATTS GF, REDGRAVE TG, MORI TA, BARRETT HR: Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentrations. Metabolism (2002) 51:1041-1046.
101. LINTON MF, FARESE RV JR, YOUNG SG: Familial hypobetalipoproteinemia. J. Lipid Res. (1993) 34:521-541.
102. NEUMAN RJ, YUAN DS, GERHARD KY et al.: Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. J. Lipid Res. (2002) 43:407-415.
103. TARUGI P, LONARDO C, GABELLI F et al.: Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. J. Lipid Res. (2001) 42:1552-1561.
104. LIAO W, YOUNG SG, DAVID R: Blocking microsomal triglyceride transfer protein interferes with apolipoprotein B secretion without causine retention or stress in the endoplasmic reticulum. J. Lipid Res. (2003) 44:978-985.
105. MAGNIN DR, BILLER SA, WETTERAU J et al.: Microsomal triglyceride transfer protein inhibitors: Discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents. Bioorg. Med. Chem. Lett. (2003) 13:1337-1340.
106. LEUNG GK, VENIANT MM, KIM SK et al.: A deficiency of microsomal triglyceride transfer protein reduced apolipoprotein B secretion. J. Biol. Chem. (2000) 275:7515-7520.
107. LIEU HD, WITHYCOMBE SK, WALKER Q et al.: Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 107:1315-1321.
108. FARESE RV JR, RULAND SL, FLYNN RP, STOKOWSKI RP, YOUNG SG: Knockout of the mouse aplipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl. Acad. Sci. USA (1995) 92:1774-1778.
109. SRIVASTAVA RA, TOTH L, SRIVASTAVA N et al.: Regulation of the apolipoprotein B gene in hyeterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. Mol. Cell. Biochem. (1999) 202:37-46.
110. BROWNING JD, HORTON JD: Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. (2004) 114:147-152.
111. HARDIE DG: Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology (2003) 144:5179-5183.
112. ZHOU G, MYERS R, LIN Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. (2001) 108:1167-1174.
113. LIN HZ, YANG SQ, CHUCKAREE C, KUHAJDA F, RONNET G, DIEHL AM: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. (2000) 6:998-1003.
114. CHANDLER CE, WILDER DE, PETTINI JL et al.: CP-436086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J. Lipid Res. (2003) 44:1887-1901.
115. SOUTSCHEK J, AKINC A, BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(11):173-178.
116. SCHOONJANS K, STAELS B, AUWERX J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. (1996) 37:907-925.
117. HAUBENWALLNER S, ESSENBURG AD, BARNETT BC et al.: Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid Res. (1995) 36:2451-2551.
118. STAELS B, DALLONGEVILLE J, AUWERX J, SCHOONJANS K, LEITERSDORF E, FRUCHART JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 98:2088-2093.
119. MINNICH A, TIAN N, BYAN L, BILDER G: A potent PPARα agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2001) 280:E270-E279.
120. GOLDBERG IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. (1996) 37:693-707.
121. DALLINGA-THIE G, BERK-PLANKEN II, BOOTSMA AH, JANSEN H: Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in Type 2 diabetes. Diabetes Care (2004) 27:1358-1364.
122. MAEDA N, LI H, LEE D, OLIVER P, QUARFORDT SH, OSADA J: Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. (1994) 269:23610-23616.
123. GINSBERG HN, LE NA, GIBSON JC et al.: Apolipoprotein B metabolism in subjects with a deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits the catabolism of triglyceride-rich lipoprotein lipase in vivo. J. Clin. Invest. (1986) 78:1287-1295.
124. GERVAISE N, GARRIGUE MA, LASFARGUES G, LECOMTE P: Triglycerides, apo C3 and LpB: C3 and cardiovascular risk in type II diabetes. Diabetologia (2000) 43:703-708.
125. TIRET L, GERDES C, MURPHY MJ et al.: Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary artery disease: the EARS II study. Eur. J. Clin. Invest. (2000) 30:578-585.
126. SUBRAMANIAM A, LEMONIDIS K, GRAHAM MJ, WHIPPLE C, CROOKE RM: ApoC-III antisense oligonucleotides reduce liver mRNA and serum triglyceride levels in hypertriglyceridemic rats. ADA Abstract (2005) (In Press).